Table V.
Cox proportional hazard regression analyses for DFS and OS in the training cohort.
| Variable | n | DFS
|
OS
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis
|
Multivariate analysis
|
Univariate analysis
|
Multivariate analysis
|
||||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Sex | |||||||||
| Female | 75 | Reference | Reference | ||||||
| Male | 105 | 1.051 (0.609-1.814) | 0.298 | NA | 1.176 (0.739-2.833) | 0.271 | NA | ||
| Age (years) | |||||||||
| ≤60 | 89 | Reference | Reference | NA | |||||
| >60 | 91 | 1.192 (0.715-1.987) | 0.180 | NA | 1.207 (0.572-2.137) | 0.170 | |||
| CEA (ng/ml) | |||||||||
| ≤5 | 110 | Reference | Reference | Reference | Reference | ||||
| >5 | 70 | 2.782 (1.948-4.083) | 0.003 | 1.615 (1.271-2.052) | 0.039 | 2.064 (1.356-3.142) | 0.008 | 1.432 (1.083-2.348) | 0.043 |
| Tumor differentiation | |||||||||
| I/II | 83 | Reference | Reference | Reference | Reference | ||||
| III/IV | 97 | 1.521 (1.034-2.416) | 0.045 | 1.007(0.634-1.629) | 0.102 | 1.773 (1.349-3.082) | 0.039 | 1.275 (0.802-2.027) | 0.218 |
| Tumor site | |||||||||
| Colon | 78 | Reference | Reference | ||||||
| Rectum | 102 | 1.206 (0.803-1.811) | 0.127 | NA | 1.216 (0.835-2.238) | 0.103 | NA | ||
| Tumor size | |||||||||
| ≤5 cm | 94 | Reference | Reference | Reference | Reference | ||||
| >5 cm | 86 | 2.033 (1.080-3.824) | 0.028 | 1.594 (0.914-2.780) | 0.073 | 2.078 (1.123-3.845) | 0.026 | 1.602 (0.923-2.781) | 0.057 |
| pT stage | |||||||||
| T1/T2 | 56 | Reference | Reference | Reference | Reference | ||||
| T3/T4 | 124 | 2.175 (1.532-4.782) | 0.012 | 1.876 (1.068-3.296) | 0.024 | 2.179 (1.723-3.835) | 0.010 | 1.832 (1.214-2.907) | 0.035 |
| pN stage | |||||||||
| N0 | 85 | Reference | Reference | Reference | Reference | ||||
| N+ | 95 | 4.309 (2.908-6.385) | <0.001 | 2.524 (1.715-3.715) | 0.001 | 4.204 (2.841-6.221) | <0.001 | 1.918 (1.534-3.235) | 0.022 |
| Lymphatic/microvascular/nerveinvasion | |||||||||
| Negative | 81 | Reference | Reference | Reference | Reference | ||||
| Positive | 99 | 3.034 (1.790-5.145) | 0.005 | 2.175 (1.532-4.782) | 0.010 | 4.914 (3.009-8.025) | <0.001 | 3.190 (1.209-3.967) | 0.001 |
| Mesenteric tumor deposit formation | |||||||||
| Negative | 114 | Reference | Reference | Reference | Reference | ||||
| Positive | 66 | 4.057 (2.485-6.623) | <0.001 | 2.323 (1.219-4.427) | 0.007 | 4.309 (2.908-6.385) | <0.001 | 2.875 (1.733-4.769) | 0.006 |
| ARHGEF7 expression | |||||||||
| Low | 72 | Reference | Reference | Reference | Reference | ||||
| High | 108 | 5.854 (3.193-10.733) | <0.001 | 3.541 (1.959-6.400) | <0.001 | 3.377 (2.135-5.342) | 0.003 | 2.050 (1.157-3.633) | 0.012 |
DFS, disease-free survival; OS, overall survival; CEA, carcinoembryonic antigen; ARHGEF7, Rho guanine nucleotide exchange factor 7.